Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rina-S in Advanced Non-Small Cell Lung Cancer
NCT07288177Phase 2Recruiting
- Sponsor
- Genmab
- Start
- Jan 2026
- Primary completion
- Nov 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 14
01
Overview
A Phase 2 trial of rinatabart sesutecan in non-small cell lung cancer (NSCLC), sponsored by Genmab. Started Jan 2026; status: recruiting.
02
Drugs
rinatabart sesutecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07288177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07288177.